Improving Outcomes in Congenital and Acquired Lipodystrophy
Best Practices in Diagnosis and Management
Guidelines
The Clinical Approach to the Detection of Lipodystrophy—A Consensus Statement From the American Association of Clinical Endocrinologists
A consensus statement from the American Academy of Clinical Endocrinologists about the classification, detection, and diagnosis of various types of lipodystrophy. The expert task force of clinical practitioners and leaders in lipodystrophy research aims to increase awareness of these underdiagnosed disorders and provide a framework for future diagnostic criteria.
Handelsman Y, et al. Endocr Pract. 2013;19(1):107-116.
Online Resources
Lipodystrophy Resource Center at The Endocrine Society
The Endocrine Society has created a variety of educational materials covering the pathophysiology, clinical presentations, and treatment of lipodystrophies. Particular emphasis is placed on the connections between generalized or partial adipose tissue loss and their often severe metabolic complications, including severe insulin resistance, type 2 diabetes, and hypertriglyceridemia.
Lipodystrophy United Website
Lipodystrophy United is an organization of committed individuals living strong with Lipodystrophy. Our mission is to provide an interactive community, facilitating support and education for anyone affected by this rare disease. We serve as a resource and to increase awareness in the general population as well as the medical and insurance communities. We advocate and act as a catalyst for new patient diagnosis by assisting healthcare professionals in the understanding of Lipodystrophy trends, physical attributes and clinical symptoms in order to aid in the advancement of knowledge, treatment and future research.
Lipodystrophy Connect Regisrty
Registry stores detailed information in one place making it easier for researchers to share and study information, while still protecting the privacy of those who take part. This research is being done to better understand LD, and to answer questions such as how LD is treated, and what can be done to improve care for people with LD.
Suggested Readings
Clinical classification and treatment of congenital and acquired lipodystrophy.
Chan JL, Oral EA. Endocr Pract. 2010;16(2):310-323.
Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL, et al. Endocr Pract. 2011;17(6):922-932.
Ectopic lipid storage and insulin resistance: a harmful relationship.
Borén J, et al. J Intern Med. 2013;274(1):25-40.
Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies.
Nolis T. J Hum Genet. 2014;59(1):16-23.
How to diagnose a lipodystrophy syndrome.
Vantyghem MC, et al. Ann Endocrinol (Paris). 2012;73(3):170-189.
Lipodystrophy: pathophysiology and advances in treatment.
Fiorenza CG, et al. Nat Rev Endocrinol. 2011;7(3):137-150.
Lipodystrophies: genetic and acquired body fat disorders.
Garg A. J Clin Endocrinol Metab. 2011;96(11):3313-3325.
Lipodystrophy: metabolic insights from a rare disorder.
Huang-Doran I, et al. J Endocrinol. 2010;207(3):245-255.
Leptin and the central nervous system control of glucose metabolism.
Morton GJ, Schwartz MW. Physiol Rev. 2011;91(2):389-411.
New advances in the treatment of generalized lipodystrophy: role of metreleptin.
Rodriguez AJ, et al. Ther Clin Risk Manag. 2015;11(1):1391-1400
Rationale for leptin-replacement therapy for severe lipodystrophy.
Oral EA, Chan JL. Endocr Pract. 2010;16(2):324-333.
Best Practices in Diagnosis and Management
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Multidimensional Outcomes With SGLT2 Inhibitors
New Avenues to Improve Patient Outcomes
Best Practices for Screening, Diagnosis, and Management
